Varamir
DeskNewsCalendarSaved
Sign in · build your desk
AYTU

Aytu Biopharma, Inc

Supply chain · Ownership · Earnings

OverviewSupply chainOwnershipNews
NewsCompanies A–ZMethodologySourcesCorrectionsTerms

Not investment advice. Not a broker-dealer. Prices: Intrinio (indices shown as ETF proxies). Supply-chain data CC BY 4.0; market data not redistributable.

Market
DeskNewsCalendarSaved
Reference
MethodologySourcesCorrectionsTerms
You
Theme
Sign in · build your desk
DeskNewsCalendarSaved
AYTUAytu Biopharma, Inc2.21▲ +1.87%
Earnings›Brief›
AYTU

Aytu Biopharma, Inc

Supply chain · Ownership · Earnings

Nasdaq · Pharmaceutical Preparations

2.21
▲ +0.04 · +1.87%
as of 20:00 UTC
open
2.21
volume
16,840
mkt cap
$23.6M
eps
-1.16
day range
2.21 – 2.21
2.21 sits 100 percent of the way through this range.
52-week
1.65 – 3.07
2.21 sits 39 percent of the way through this range.
next earningsNov 10 · in 42d · after closeafter close · est.
EarningsExpected move · positioning · linked exposure›Briefprint›

Changes

last 30 days

No changes in the last 30 days.

Intraday

▲ +0.02% since 10 AM
10 AM12 PM3 PM4 PM
2.212.212.212.21prev2.212.21

High 2.21 4:00 pm · Low 2.21 10:45 am ET

Who supplies Aytu Biopharma, Inc, and who buys from it

Aytu Biopharma, Inc has 5 disclosed suppliers and 2 disclosed customers in SEC filings.

Who supplies Aytu Biopharma, Inc?

5 disclosed

5 disclosed: Halo Pharmaceutical, Inc, Mission Pharmacal Company, Tris Pharma, Inc. and 2 more.

  1. 1—Halo Pharmaceutical, Inc
  2. 2—Mission Pharmacal Company
  3. 3—Tris Pharma, Inc.
  4. 4—Fabre-Kramer Holdings, Inc.
  5. 5—Tris

Who buys from Aytu Biopharma, Inc?

2 disclosed

2 disclosed: Lupin and Lupin Pharma Canada Ltd; 1 is a partnership or agreement.

  1. 1—Lupin
  2. 2—Lupin Pharma Canada Ltd

Sources

sec edgar · verbatim disclosure

Sources for AYTU relationships

Show sources· 7›
  1. —Halo Pharmaceutical, Incbuys from›
    “Some of our products are produced infrequently and by single-source suppliers, including but not limited to Halo Pharmaceutical, Inc, Mission Pharmacal Company, and Tris Pharma.”

    10-K0001437749-26-030908filed Sep 22 '26

  2. —Mission Pharmacal Companybuys from›
    “Some of our products are produced infrequently and by single-source suppliers, including but not limited to Halo Pharmaceutical, Inc, Mission Pharmacal Company, and Tris Pharma.”

    10-K0001437749-26-030908filed Sep 22 '26

  3. —Tris Pharma, Inc.buys from›
    “Some of our products are produced infrequently and by single-source suppliers, including but not limited to Halo Pharmaceutical, Inc, Mission Pharmacal Company, and Tris Pharma.”

    10-K0001437749-26-030908filed Sep 22 '26

  4. —Fabre-Kramer Holdings, Inc.buys from›
    “EXXUA is purchased through Fabre-Kramer through their manufacturing agreement with a CMO, as part of our exclusive commercialization agreement with Fabre-Kramer.”

    10-K0001437749-26-030908filed Sep 22 '26

  5. —Trisbuys from›
    “Pursuant to such termination we accrued a settlement liability, which as of June 30, 2025, had a remaining balance of $3.1 million accrued in other current liabilities on the consolidated balance sheet payable to Tris, which was paid in full during the first quarter of fiscal 2026.”

    10-K0001437749-26-030908filed Sep 22 '26

  6. —Lupinsells to›
    “Our future profitability may depend, in part, on our ability to commercialize our products in foreign markets for which we intend to primarily rely on collaboration with third parties such as the agreement we entered into with Lupin in September 2024 to commercialize Adzenys and Cotempla in Canada.”

    10-K0001437749-26-030908filed Sep 22 '26

  7. —Lupin Pharma Canada Ltdsells to›
    “We will supply Adzenys and Cotempla to Lupin based on forecasts and provide various product commercialization, regulatory and quality assurance resources.”

    10-K0001437749-26-030908filed Sep 22 '26

Supply chain

SEC · 7 direct ties

AYTU (Aytu Biopharma, Inc) has 5 disclosed suppliers and 2 disclosed customers, strongest disclosure first.

Suppliers:

  1. Halo Pharmaceutical, Inc, price pending
  2. Mission Pharmacal Company, price pending
  3. Tris Pharma, Inc., price pending
  4. Fabre-Kramer Holdings, Inc., price pending
  5. Tris, price pending

Customers:

  1. Lupin, price pending
  2. Lupin Pharma Canada Ltd, price pending
100%
expand

Distance from centre = disclosure strength · Extended: 2nd-degree ties, single companies only